Effect of pressure therapy for treatment of hypertrophic scar

Hao Zhang, MBa,†, Hao-yan Wang, MMb, Da-li Wang, MBc, Xiao-dong Zhang, MBa

Abstract

Background: Pressure therapy (PST) has been reported for the treatment of hypertrophic scar (HS) effectively. However, no study has assessed its effect and safety systematically. Therefore, this study will investigate its effect and safety for patients with HS.

Methods: A comprehensive literature search will be performed from the electronic databases and grey literatures. The electronic databases include MEDILINE, EMBASE, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. All of them will be searched from inception to the present without language restrictions. Any randomized controlled trials on assessing the effect and safety of PST on HS will be considered for inclusion. In addition, we will also search grey literature to avoid missing any potential studies. RevMan V.5.3 software will be utilized for statistical analysis.

Results: This study will provide the most recent evidence of PST on HS by evaluating primary outcomes of scar pruritus and improvement of scar; and secondary outcomes of scar blood flow, elasticity, volume, pain and burning. In addition, we will also evaluate adverse events.

Conclusion: This study will provide up-to-date evidence of PST in patients with HS.

Systematic review registration: PROSPERO CRD42019136627.

Abbreviations: CIs = confidence intervals, HS = hypertrophic scar, PRISMA = Reporting Items for Systematic Reviews and Meta-Analysis Protocol, PST = pressure therapy, RCTs = randomized controlled trials.

Keywords: effect, hypertrophic scar, pressure therapy, safety

1. Introduction

Hypertrophic scar (HS) is a kind of visible and elevated scar, which often does not spread into surrounding tissues and regress spontaneously.[1–3] It is often characterized by proliferation of the dermal tissue. This tissue often accompanies excessive deposition of fibroblast-derived extracellular matrix proteins and especially collagen, which lasts long term with persistent inflammation and fibrosis.[4–6]

A variety of managements are reported to treat this disorder.[7–20] These managements include small-wave incision, intralesional interferon, streptomycin/lignocaine local infiltration, topical and intralesional corticosteroids, intralesional bleomycin, laser therapy, silicone gel, and pressure therapy (PST).[7–20] However, up to date, the optimal treatment method has not been established. Although several clinical studies have reported that PST can treat HS effectively,[21–23] no systematic review has been conducted to assess its effect and safety in patients with HS. Thus, in this study, we will systematically investigate its effect and safety in patients with HS.

2. Methods

2.1. Ethics and dissemination

This study does not require ethic approval because we will not analyze individual patient data. This study will be published on peer-reviewed journals.

2.2. Registration

This study has been registered in the PROSPERO with number of CRD42019136627. We will report this study in accordance with the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Protocol statement.[26]

2.3. Eligibility criteria

2.3.1. Types of studies. All randomized controlled trials (RCTs) assessing the effect and safety of PST in patients with HS will be included. However, we will exclude non-clinical studies, non-RCTs, and quasi-RCTs.

2.3.2. Types of participants. Participants with HS will be included in this study regardless their race, age, gender, and economic status.
2.3.3. Types of treatments. Experimental group: patients receive PST for HS. Control group: patients receive any treatments except HS.

2.3.4. Types of outcome measurements. Primary outcomes include scar pruritus, as measured by 4-item Itch Questionnaire or any other associated scales; and improvement of scar, as assessed by photography or relevant tools.

Secondary outcomes consist of clinic measurements of scar blood flow, elasticity, and volume; and patients’ subjective complaints of pain and burning; as well as adverse events.

2.4. Data sources and search strategy

We will perform a comprehensive literature search from the electronic databases of MEDLINE, EMBASE, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception to the present without language restrictions. The comprehensive search strategy for MEDLINE is presented in Table 1. Similar search strategy will be adapted to any other electronic databases. Additionally, we will also search grey literature, such as dissertations, clinical registry, and reference lists of relevant reviews.

2.5. Data collection and management

2.5.1. Study selection. Two reviewers will independently perform study selection according to the predefined eligibility criteria. Any different opinions regarding the study selection between 2 reviewers will be settled down by a third reviewer through discussion. The whole process will consist of 2 steps. First, all searched literature will be scanned by titles and abstracts, and all irrelevant studies will be excluded. Second, all remaining literature will be read by full-texts and will be further judged if they meet final eligibility criteria. We will present the results of study selection in PRISMA flow diagram.

2.5.2. Data extraction. Two reviewers will independently perform data extraction in accordance with predefined data extraction sheet. A third reviewer will help to solve any disagreements between 2 reviewers. The extracted information includes study information (such as title, author, region, etc), patient characteristics (such as age, sex, diagnostic criteria, etc), study methods (such as sample size, randomization, concealment, blinding, etc), treatment methods (such as intervention name, dosage, frequency, duration, etc), and outcome measurements (such as primary and secondary outcomes, and safety).

2.5.3. Missing data management. If there is insufficient or missing data, we will contact primary corresponding author via email to request that. If that data will not be achievable, only available data will be analyzed. In addition, the potential impacts of missing data will be discussed.

2.6. Methodological quality assessment

Cochrane risk of bias tool will be used to assess the methodological quality for each eligible study. Two reviewers will independently assess the methodological quality for all eligible studies. Any disagreements regarding the methodological quality assessment will be worked out by a third reviewer through discussion. This tool comprises of 7 domains, and each one is further judged as high, unclear, and low risk of bias.

2.7. Statistical analysis

RevMan V.5.3 software will be used to operate statistical analysis. The risk ratio and 95% confidence intervals (CIs) will be utilized to express dichotomous data. A weighted mean difference or a standard mean difference with 95% CIs will be employed to present continuous outcomes.

We will use I² statistic test to check heterogeneity among eligible studies. If the value of I² is less than 50%, reasonable heterogeneity is identified, and a fixed-effect model will be used to pool the data. Otherwise, if the value of I² is more than 50%, significant heterogeneity is identified, and a random-effect model will be used to pool the data. Additionally, we will also perform subgroup analysis to explore any possible factors for substantial heterogeneity. We will carry out meta-analysis if heterogeneity is reasonable. If there is still substantial heterogeneity after subgroup analysis, we will not perform data pooling and meta-analysis. Instead, we will report narrative summary.

Subgroup analysis will be conducted based on the different study, interventions, controls, and outcomes. In addition, we will carry out sensitivity analysis to check the stability and robustness of outcome results by removing low quality studies. Furthermore, funnel plots and Egger linear regression test will also be carried out if more than 10 eligible studies are entered in this study.

3. Discussion

This study will investigate the effect and safety of PST in patients with HS systematically. A comprehensive literature search will be performed without any language restrictions. We will also retrieve grey literature to avoid missing any potential eligible studies. Two reviewers will independently carry study selection, data extraction, and methodological quality assessment. Any divergences between 2 reviewers will be solved by a third reviewer through discussion. The findings of this study will summarize the latest evidence on assessing the effect and safety of PST in patients.
with HS. It may benefit either the future research or the clinical practice.

**Author contributions**

Conceptualization: Hao Zhang, Da-li Wang, Xiao-dong Zhang.

Data curation: Hao Zhang, Hao-yan Wang, Xiao-dong Zhang.

Formal analysis: Hao-yan Wang, Da-li Wang, Xiao-dong Zhang.

Funding acquisition: Hao Zhang.

Investigation: Hao Zhang.

Methodology: Hao-yan Wang, Da-li Wang, Xiao-dong Zhang.

Project administration: Hao Zhang.

Resources: Hao-yan Wang, Da-li Wang, Xiao-dong Zhang.

Software: Hao-yan Wang, Da-li Wang, Xiao-dong Zhang.

Supervision: Hao Zhang.

Validation: Hao Zhang, Da-li Wang, Xiao-dong Zhang.

Visualization: Hao Zhang, Hao-yan Wang, Xiao-dong Zhang.

Writing – original draft: Hao Zhang, Hao-yan Wang, Da-li Wang.

Writing – review & editing: Hao Zhang, Hao-yan Wang, Da-li Wang, Xiao-dong Zhang.

**References**

[1] Zhang YQ, Dong JY, Wang C, et al. Clinical effects of a combination treatment with narrow-spectrum intense pulsed light and fractional carbon dioxide laser on hypertrophic scar pruritus. Zhonghua Shao Shang Za Zhi 2018;34:608–14.

[2] Zhang J, Li Y, Bai X, et al. Recent advances in hypertrophic scar. Histol Histopathol 2018;33:27–39.

[3] Chen L, Li J, Li Q, et al. Non-coding RNAs: the new insight on hypertrophic scar. J Cell Biochem 2017;118:1965–8.

[4] Gabriel V. Hypertrophic scar. Phys Med Rehabil Clin N Am 2011;22:301–10.

[5] Huang C, Ong J, Ogawa R. The link between hypertension and pathological scarring: does hypertension cause or promote keloid and hypertrophic scar pathogenesis? Wound Repair Regen 2014;22:462–6.

[6] Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg 2007;31:468–92.

[7] Huang C, Ong J, Ogawa R, et al. Small-wave incision method for linear hypertrophic scar reconstruction: a parallel-group randomized controlled study. Aesthetic Plast Surg 2012;36:387–95.

[8] Bloemen MC, van der Veer WM, Ulrich MM, et al. Prevention and curative management of hypertrophic scar formation. Burns 2009;35:463–75.

[9] Li-Tsang CW, Lau JC, Choi J, et al. A prospective randomized clinical trial to investigate the effect of silicone gel sheeting (Cica-Care) on post-traumatic hypertrophic scar among the Chinese population. Burns 2006;32:678–83.

[10] Chan KY, Lau CL, Adeeb SM, et al. A randomized, placebo-controlled, double-blind, prospective clinical trial of silicone gel in prevention of hypertrophic scar development in median sternotomy wound. Plast Reconstr Surg 2005;116:1013–20.

[11] Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 2006;8:362–8.

[12] Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon 2007;5:175–80.

[13] Naemni FF, Najafian J, Ahmadpour K. Bleomycin tattooing as an promising therapeutic modality in large keloids and hypertrophicscars. Dermatol Surg 2006;32:1023–9.

[14] Kumar A, Agarwal M, Bhattacharya A. Streptomycin/lignocaine A. Streptomyacin/lignocaine local infiltration in the treatment of hypertrophic scar pain. A preliminary report. Acta Anaesthesiol Scand 1997;41:546.

[15] Fan ZH, Guan WX, Jin YT. Silicone gel in the treatment of burn and prevention of hypertrophic scar. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1993;9:385–7.

[16] Leclère FM, Mordon SR. Twenty-five years of active laser prevention of scars: what have we learned. J Cosmet Laser Ther 2010;12:227–34.

[17] O’Brien L, Pandit A. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2013;9:CD003826.

[18] Shih R, Waltzman J, Evans GR. Plastic Surgery Educational Foundation Technology Assessment Committee Report of over-the-counter topical scar treatment products. Plast Reconstr Surg 2007;119:1091–5.

[19] Carr-Collins JA. Pressure techniques for the prevention of hypertrophic scar. Clin Plast Surg 1992;19:733–43.

[20] Ward RS. Pressure therapy for the control of hypertrophic scar formation after burn injury. A history and review. J Burn Care Rehabil 1991;12:257–62.

[21] Haq MA, Haq A. Pressure therapy in treatment of hypertrophic scar, burn contracture and keloid: the Kenyan experience. East Afr Med J 1990;67:785–93.

[22] Harte D, Gordon J, Shaw M, et al. The use of pressure and silicone in hypertrophic scar management in burns patients: a pilot randomized controlled trial. J Burn Care Res 2009;30:632–42.

[23] Candy LH, Cecilia LT, Ping ZY. Effect of different pressure magnitudes on hypertrophic scar in a Chinese population. Burns 2010;36:1234–41.

[24] Li-Tsang CW, Feng BB, Li KC. Pressure therapy of hypertrophic scar after burns and related research. Zhonghua Shao Shang Za Zhi 2010;26:411–5.

[25] Tan J, Fu JF. Effects of pressure therapy on the proliferation and apoptosis of cells in hypertrophic scar of burn patients. Zhonghua Shao Shang Za Zhi 2013;29:509–15.

[26] Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.